Published in Carcinogenesis on January 03, 2008
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics. Hum Genet (2008) 1.57
Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate (2009) 1.45
Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis (2011) 1.10
Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis (2009) 1.09
Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk. PLoS One (2013) 0.99
Association between tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis. Diagn Pathol (2014) 0.92
The interleukin 10 -819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. OMICS (2013) 0.92
Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Prostate (2015) 0.91
Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis (2012) 0.85
The interleukin-10 promoter polymorphism rs1800872 (-592C>A), contributes to cancer susceptibility: meta-analysis of 16,785 cases and 19,713 controls. PLoS One (2013) 0.85
-174G/C polymorphism in the interleukin-6 promoter is differently associated with prostate cancer incidence depending on race. Genet Mol Res (2014) 0.84
TRM: a powerful two-stage machine learning approach for identifying SNP-SNP interactions. Ann Hum Genet (2011) 0.81
Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer. Clinics (Sao Paulo) (2011) 0.81
EPAS1 gene variants are associated with sprint/power athletic performance in two cohorts of European athletes. BMC Genomics (2014) 0.79
Vitamin D and Immune Response: Implications for Prostate Cancer in African Americans. Front Immunol (2016) 0.78
Inflammatory genetic markers of prostate cancer risk. Cancers (Basel) (2010) 0.78
Associations of IL-10 genetic polymorphisms with the risk of urologic cancer: a meta-analysis based on 18,415 subjects. Springerplus (2016) 0.75
The impact of genetic variants in inflammatory-related genes on prostate cancer risk among men of African Descent: a case control study. Hered Cancer Clin Pract (2013) 0.75
The impact of interleukin-10 (IL-10) gene 4 polymorphisms on peripheral blood IL-10 variation and prostate cancer risk based on published studies. Oncotarget (2017) 0.75
Interleukin 10 gene rs1800896 polymorphism is associated with the risk of prostate cancer. Oncotarget (2017) 0.75
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis (2009) 4.96
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 4.74
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev (2008) 4.40
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 3.80
The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care STDS (2009) 3.78
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol (2012) 3.30
A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol (2007) 3.26
Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet (2013) 3.25
L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood (2006) 3.17
The influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival: an analysis of the Survival, Epidemiology, and End Results database. Cancer (2012) 3.12
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
The landscape of recombination in African Americans. Nature (2011) 3.06
L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol (2003) 2.91
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2010) 2.80
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet (2011) 2.70
Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem (2002) 2.62
Racial disparities in HIV virologic failure: do missed visits matter? J Acquir Immune Defic Syndr (2009) 2.58
Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol (2011) 2.51
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol (2010) 2.39
Failure to establish HIV care: characterizing the "no show" phenomenon. Clin Infect Dis (2007) 2.37
Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol (2007) 2.20
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol (2010) 2.03
A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology (2004) 1.99
Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res (2009) 1.99
Recovery of urinary function after radical prostatectomy: identification of trajectory cluster groups. J Urol (2012) 1.98
Enhanced statistical tests for GWAS in admixed populations: assessment using African Americans from CARe and a Breast Cancer Consortium. PLoS Genet (2011) 1.94
Canaries in the coal mine: a cross-species analysis of the plurality of obesity epidemics. Proc Biol Sci (2010) 1.86
National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol (2012) 1.84
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol (2012) 1.77
Urinary diversion trends at a high volume, single American tertiary care center. J Urol (2009) 1.73
Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol (2011) 1.72
Comparison of transfusion requirements between open and robotic-assisted laparoscopic radical prostatectomy. BJU Int (2010) 1.66
Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. Carcinogenesis (2008) 1.64
LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res (2011) 1.64
Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One (2012) 1.63
Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev (2010) 1.62
Smaller prostate size predicts high grade prostate cancer at final pathology. J Urol (2010) 1.62
Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success. AJR Am J Roentgenol (2004) 1.56
Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol (2009) 1.55
Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Urology (2012) 1.53
Decreased expression of CD3zeta and nuclear transcription factor kappa B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. J Infect Dis (2006) 1.53
Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. BJU Int (2012) 1.52
Is the R.E.N.A.L. nephrometry scoring system predictive of the functional efficacy of nephron sparing surgery in the solitary kidney? J Urol (2012) 1.51
Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol (2010) 1.50
Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res (2003) 1.49
Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Prostate (2014) 1.49
ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol (2012) 1.49
Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev (2009) 1.49
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47
Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry. PLoS Genet (2011) 1.47
Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response. Proc Natl Acad Sci U S A (2005) 1.46
L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol (2005) 1.45
Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans. Hum Mol Genet (2011) 1.45
Consistent condom use reduces the genital human papillomavirus burden among high-risk men: the HPV infection in men study. J Infect Dis (2013) 1.43
Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest (2012) 1.43
The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res (2004) 1.41
Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer (2009) 1.41
Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study. J Infect Dis (2011) 1.40
Helicobacter pylori arginase inhibits T cell proliferation and reduces the expression of the TCR zeta-chain (CD3zeta). J Immunol (2004) 1.37
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer (2013) 1.37
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Contemporary open radical cystectomy: analysis of perioperative outcomes. J Urol (2008) 1.34
Bladder cancer. J Natl Compr Canc Netw (2009) 1.32
Quercetin, but not rutin and quercitrin, prevention of H2O2-induced apoptosis via anti-oxidant activity and heme oxygenase 1 gene expression in macrophages. Biochem Pharmacol (2005) 1.30
Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone. J Urol (2002) 1.30
Bladder cancer. Curr Opin Oncol (2008) 1.29
Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer. Mol Cell Biol (2009) 1.28
Design, synthesis, and preclinical evaluation of new 5,6- (or 6,7-) disubstituted-2-(fluorophenyl)quinolin-4-one derivatives as potent antitumor agents. J Med Chem (2010) 1.28
Bladder cancer. Curr Opin Oncol (2009) 1.26
Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res (2004) 1.24
Unequal burden of head and neck cancer in the United States. Head Neck (2008) 1.22
DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2003) 1.20
Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol (2007) 1.20
DNA damage and breast cancer risk. Carcinogenesis (2003) 1.19
Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade- and mitochondria-dependent pathways. Anticancer Res (2010) 1.18
Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol (2002) 1.16
Purification and characterization of Helicobacter pylori arginase, RocF: unique features among the arginase superfamily. Eur J Biochem (2004) 1.16
T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin Cancer Biol (2005) 1.16
Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol (2002) 1.15
Ethnic differences in cytokine gene polymorphisms: potential implications for cancer development. Cancer Immunol Immunother (2007) 1.15
Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic. Clin Infect Dis (2010) 1.14
Gallic acid suppresses the migration and invasion of PC-3 human prostate cancer cells via inhibition of matrix metalloproteinase-2 and -9 signaling pathways. Oncol Rep (2011) 1.14